Transaction · 0001866174-26-000011

Walsh Colin

WALSH COLIN, DIR, reported an open-market or private purchase at Attovia Therapeutics, Inc. involving 500000.000000 shares for an estimated $8500000.00. Reported holdings after the transaction were 3020632.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code PDIR
ATTOAttovia Therapeutics, Inc.
Trade date
Aug 06, 2026
Filing date
Aug 28, 2026
View on SEC Insider profile
Estimated value$8.50MShares × reported price
Shares traded500k$17.00 per share
Holdings after3.02MIndirect · See Footnotes
% of reported position traded19.84%This security and ownership context
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 2,520,632 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
2 warnings
amended filingThis transaction comes from an amended Form 4 filing.
delayed filingThe filing was reported 22 calendar days after the transaction date.

ATTO price since this filing

Daily closing prices, with the filing date and available return windows
ATTO · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001866174-26-000011
Common Stock
Transaction date
Aug 06, 2026
Filed Aug 28, 2026, 09:38 PM · 22d delay
Shares
500,000 sh
$17.00 per share
Estimated value
$8.50M
Computed from shares × price
Holdings after
3,020,632 sh
Indirect · See Footnotes

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Amended Filing Cluster Buy Delayed Filing Director Buy Large Buy Repeat Buyer
Filing-only score

+44 points

Compact filing score computed from stored Form 4 facts. Version v1.

Strong filing signal

This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.

How this score is calculated
  • open_market_purchase+12 points

    transaction_code = P

    Code P is a discretionary open-market purchase.
  • director_buy+6 points

    is_director = true

    Director open-market purchase.
  • cluster_buy+14 points

    cluster-buy signal matched

    Multiple insiders bought within the configured window.
  • repeat_buyer+8 points

    repeat-buyer signal matched

    Same insider bought again within the configured window.
  • large_buy_absolute+10 points

    large-buy signal with absolute_triggered = true

    Open-market purchase exceeds the configured absolute threshold.
  • large_buy_historical+6 points

    large-buy relative_triggered with sample 7

    Open-market purchase exceeds the historical median by the configured multiple.
  • amended_filing-6 points

    is_amendment = true

    Amended filing: the original transaction may have been restated.
  • delayed_filing-6 points

    reporting_delay_days = 22

    Filing delay exceeds the configured threshold.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be de…

  2. F2

    These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without concedin…

  3. F3

    GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long…

  4. F4

    The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4.…

  5. F5

    Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 9.29-for-1 basis upon the closing of t…

  6. F6

    The Reporting Person is a managing director of GS&Co, a subsidiary of The Goldman Sachs Group Inc. ("GS Group"). GS Group is the direct owner of GS&Co and an indirect owner of Goldman Sachs Asset Mana…

  7. F7

    (continued from footnote 6)... West Street Life Sciences I, L.P. ("WSLS I") which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5…

  8. F8

    (continued from footnote 7)... GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GS…

Amended filing · 0001866174-26-000011
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ATTO